Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 725 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-PD1 Clear all

Conditions: Metastatic Melanoma
Interventions: AV-MEL-1; Drug
Lead sponsor: Aivita Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Irvine, California • Newport Beach, California

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 35
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more

Conditions: Soft Tissue Sarcoma, Bone Sarcoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 12 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 9 more

Conditions: Nonsquamous Non-small Cell Lung Cancer
Interventions: Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed; Combination Product
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Glendale, Arizona • Norwich, Connecticut • Fredericksburg, Virginia

Conditions: Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions: iSCIB1+, Nivolumab & Ipilimumab, Placebo; Biological · Drug · Other
Lead sponsor: Scancell Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Carboplatin, Pembrolizumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Biliary Tract Cancer
Interventions: Rucaparib, Nivolumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Advanced/Metastatic Solid Tumors
Interventions: ADG126 Mono, ADG126-anti PD1, ADG126-ADG106; Biological
Lead sponsor: Adagene Inc; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • San Antonio, Texas

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: aerosolized aztreonam, aerosolized vancomycin, pembrolizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions: Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, Durvalumab, Erlotinib Hydrochloride, FGFR Inhibitor AZD4547, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Palbociclib, Pharmacological Study, Rilotumumab, Talazoparib, Taselisib, Tremelimumab; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 998
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more

Conditions: Biliary Tract Cancer
Interventions: XmAb20717; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Abexinostat, Pembrolizumab; Drug · Biological
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Melanoma
Interventions: Olaparib, Pembrolizumab; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Lanreotide, Pembrolizumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Durham, North Carolina • Columbia, South Carolina

Conditions: Glioblastoma (GBM)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Limited Stage Small Cell Lung Cancer
Interventions: BMS-986489, Durvalumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 34
States / cities: Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more

Conditions: Bladder Cancer
Interventions: PF-07225570, sasanlimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Metastatic Merkel Cell Carcinoma
Interventions: Retifanlimab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Melanoma Stage III, Melanoma Stage IV
Interventions: L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®; Drug
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Hartford, Connecticut • New York, New York

Conditions: Cancer
Interventions: Vopratelimab, Ipilimumab, Nivolumab; Drug
Lead sponsor: Jounce Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: St Louis, Missouri • Houston, Texas • Charlottesville, Virginia

Conditions: Recurrent Human Papillomavirus Type 16 Associated Cancer
Interventions: HPV 16 TA-CIN; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Search by objective public record fields.

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

The Seven Trial: Exploiting the Unfolded Protein Response

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

XmAb20717 in Advanced Biliary Tract Cancers

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers